Skip to main content

Advertisement

Log in

Infantile Hemangiomas: Complications and follow-up

  • Research Paper
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

Objective

To study the risk factors for hemangioma-related complications, treatment indications and analyze the outcome of patients with infantile hemangioma.

Design

Retrospective.

Setting

University hospital.

Patients

Fifty-five patients (1–69 months; median: 12 months) with infantile hemangioma with mean follow-up 19 months. The eligibility was based on the criteria of the International Society for the Study of Vascular Anomalies (ISSVA).

Intervention

The surgical treatment included total excision whereas medical treatment was carried out by interferon and /or corticosteroids.

Main outcome measures

Data was collected including sex, age, prematurity, age at onset, number, anatomic location and size of hemangioma, age at treatment, cause of treatment decision, family history, presence of extra malformations, involvement of internal organs, presence of life altering or life threatening complications, response to treatment, dose and duration of medications, complications associated with treatment, follow-up period, and final outcome.

Results

Thirty-four (62%) patients were followed-up without treatment, whereas 21 others underwent treatment including steroids, interferon, and surgery. The size of hemangioma was a major factor that predicted hemangioma-related complications (P=0.002). Patients with hemangioma related complications had bigger lesions (size ≥40cm2 or the longest size on a single plane ≥5 cm). Nineteen patients (34%) had complications, but only 8 (14.5%) out of them had life or function-threatening complications.

Conclusion

Although dosing and treatment protocol is still debatable, steroids and interferon are good options for hemangioma treatment. The management strategy should be individualized for each case.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, et al. Infantile hemangiomas: current knowledge, future directions. proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005;22:383–406.

    Google Scholar 

  2. Barrio VR, Drolet BA. Treatment of hemangiomas of infancy. Dermatol Ther. 2005;18:151–159.

    Article  PubMed  Google Scholar 

  3. Werner JA, Düne AA, Lippert BM, Folz BJ. Optimal treatment of vascular birthmarks. Am J Clin Dermatol. 2003;4:745–756.

    Article  PubMed  Google Scholar 

  4. Tansg MW, Garzon MC, Freiden IJ. How to measure a growing hemangioma and assess response to therapy. Pediatr Dermatol. 2006;23:187–190.

    Article  Google Scholar 

  5. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48:477–493.

    Article  PubMed  Google Scholar 

  6. Pandey A, Gangopadhyay AN, Gopal SC, Kumar V, Sharma SP, Gupta DK, et al. Twenty years’ experience of steroids in infantile hemangioma-a developing country’s perspective. J Pediatr Surg. 2009;44:688–694.

    Article  PubMed  Google Scholar 

  7. Mulliken JB, MD, Enjolras O. Congenital hemangiomas and infantile hemangioma: Missing links. J Am Acad Dermatol. 2004;50:875–882.

    Article  PubMed  Google Scholar 

  8. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, et al. Prospective study of infantile hemangiomas: Clinical charactheristics predicting complications and treatment. J Pediatr. 2006;118:882–887.

    Article  Google Scholar 

  9. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122:360–367.

    Article  PubMed  Google Scholar 

  10. Garzon MC, Drolet BA, Baselga E, Chamlin SL, Haggstrom AN, Horii K, et al. Comparison of infantile hemangiomas in preterm and term infants: A prospective study. Arch Dermatol. 2008;144:1231–1232.

    Article  PubMed  Google Scholar 

  11. Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011;128: 743–752.

    Article  PubMed  CAS  Google Scholar 

  12. Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol. 2001:44:962–972.

    Article  PubMed  CAS  Google Scholar 

  13. Frieden IJ. Which hemangiomas to treat-and how? Arch Dermatol. 1997;133:1593–1595.

    Article  PubMed  CAS  Google Scholar 

  14. Chamlin SL, Haggstrom AN, Drolet BA, Baselge E, Frieden IJ, Garzon MC, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr. 2007;151:684–689.

    Article  PubMed  Google Scholar 

  15. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104:1616–1623.

    Article  PubMed  CAS  Google Scholar 

  16. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140:963–969.

    Article  PubMed  CAS  Google Scholar 

  17. Jiménez-Hernández E, Dueñas-González MT, Quintero-Curiel JL, Velásquez-Ortega J, Magaña-Pérez JA, Berges-García A, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg. 2008;34:640–647.

    Article  PubMed  Google Scholar 

  18. Greinwald JH, Burke DK, Bonthius DJ, Bauman NM, Smith RJH. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolayngol Head Neck Surg. 1999:125:21–27.

    Google Scholar 

  19. Dubois J, Hershon L, Carmant L, Belanger S, Leclerc JM, David M. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr. 1999;135:782–785.

    Article  PubMed  CAS  Google Scholar 

  20. Itinteang T, Withers AH, Leadbitter P, Day DJ, Tan ST. Pharmacologic therapies for infantile hemangioma: is there a rational basis? Plast Reconstr Surg. 2011;128:499–507.

    Article  PubMed  CAS  Google Scholar 

  21. Enjolras O, Breviere GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11:99–107.

    Article  PubMed  CAS  Google Scholar 

  22. Zide BM, Levine SM. Hemangioma update: pearls from 30 years of treatment. Ann Plast Surg. 2011 Jul 5. [E-pub ahead of print].

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arzu Akcay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akcay, A., Karakas, Z., Saribeyoglu, E.T. et al. Infantile Hemangiomas: Complications and follow-up. Indian Pediatr 49, 805–809 (2012). https://doi.org/10.1007/s13312-012-0193-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-012-0193-3

Key words

Navigation